ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

aTYR PHARMA INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026

$0.17−0.00 (-1.32%)

Close on Oct 19, 2026

Market cap: $16.84M
P/E (TTM): –
Dividend yield: –

aTYR PHARMA INC income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31
Revenue	0.19	0.24	0.35	10	0	10	0.42	–	–	–	–	–	–
Research & Development	60	54	42	43	23	17	14	20	30	43	35	17	14
General & Administrative	18	14	13	14	11	9.08	9.35	12	17	15	13	6.78	5.71
Operating Expenses	78	68	55	57	34	26	23	33	47	58	48	24	20
Operating Income	-78	-68	-55	-46	-34	-16	-23	-33	-47	-58	-48	-24	-20
Other Non-Operating Income	3.50	3.89	4.52	1.06	0.24	-0.32	-0.79	-1.70	-1.06	0.04	-0.36	-0.80	-0.47
Asset Impairment Charges	0	0	0	0	0	0	0	0	0	0	0	–	–
Gain (Loss) on Sale of Assets	0.01	0.00	0.01	0.09	-0.01	0.00	0.03	-0.02	–	–	–	–	–
Pretax Income	-74	-64	-50	-45	-34	-16	-24	-35	-48	-58	-48	-24	-20
Income Tax Expense	0	0	0	0	0	0	0	0	–	-0.05	–	–	–
Net Income incl. Noncontrolling Interests	-74	-64	-50	-45	-34	-16	-24	-35	-48	-58	–	–	–
Minority Interest in Earnings	-0.01	0.00	-0.01	-0.01	-0.01	-0.01	-0.16	–	–	–	–	–	–
Net Income	-74	-64	-50	-45	-34	-16	-16	-35	-48	-58	-48	-24	-20
Net Income to Common	–	–	–	–	–	–	–	–	-48	-58	-48	-25	-22
EPS (Basic)(per share)	-0.80	-0.86	-0.94	-1.60	-1.77	-1.77	-7.03	-16.11	-26.13	-34.16	-42.42	-415.66	-397.46
EPS (Diluted)(per share)	-0.80	-0.86	-0.94	-1.60	-1.77	-1.77	-7.03	-16.11	-26.13	-34.16	-42.42	-415.66	-397.46
Shares Outstanding (Basic, Weighted)(shares)	93	74	54	28	19	9.16	3.36	2.14	1.85	1.69	1.13	0.06	0.05
Shares Outstanding (Diluted, Weighted)(shares)	93	74	54	28	19	9.16	3.36	2.14	1.85	1.69	1.13	0.06	0.05
EBITDA	-77	-67	-54	-46	-34	-15	-22	-32	-46	-57	-47	-23	-19

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, FY2025

Gross margin: –
Operating margin: -33609.5%
Net margin: -32003.7%
Return on equity, FY2025: -107.8%

Financial strength

Current ratio: 5.12
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 141.8%

Valuation

P/E ratio: –
Price to sales: 88.62
Price to book: 0.35
Dividend yield: –